This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As oncology continues to dominate the pharmaceutical market, the global demand for effective cancer therapies has reached unprecedented levels. With advances in precision medicine and immunotherapy driving innovation, leading oncology drugs are not only transforming treatment paradigms but also generating billions in revenue. The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global can
In an article published online this week , leaders from the NIH Pragmatic Trials Collaboratory share lessons learned about the collection of patient-reported outcome measures (PROMs) in medically underserved patients, including people with incomes below the federal poverty threshold, racial or ethnically minoritized groups, and rural and frontier communities.
The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.
The US Food and Drug Administration (FDA) has approved Attruby (acoramidis) , marking a significant advancement for patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This progressive disease occurs when misfolded transthyretin (TTR) proteins form amyloid deposits in the heart, leading to cardiac dysfunction. Attruby offers a near-complete stabilization of TTR — over 90 percent — halting the formation of amyloid fibrils that cause tissue damage and addressing the underlying p
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in a closely followed Phase 3 study called SKYSCRAPER-01.
(SciePro/Science Photo Library/Getty Images) Stem cells are special in the way they can keep on replicating, and turn themselves into many other types of cell. Now scientists have discovered how their superpowers get a remarkable boost when they’re grown in space.
(SciePro/Science Photo Library/Getty Images) Stem cells are special in the way they can keep on replicating, and turn themselves into many other types of cell. Now scientists have discovered how their superpowers get a remarkable boost when they’re grown in space.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Discover the revolutionary impact of generative artificial intelligence (GenAI) on drug safety in pharmacovigilance. Learn how this cutting-edge technology is transforming the industry.
Moderna's missteps serve as a reminder of the importance of regulatory bodies like PMCPA in upholding ethics within the pharmaceutical industry. Learn more about their role and impact.
In 2001, a Time Magazine cover story touted Novartis’ targeted leukemia treatment Gleevec (imatinib) as a new kind of “am | Shorla Oncology has scored an FDA approval for its strawberry-flavored drink version of Novartis' cancer drug Gleevec. Dubbed Imkeldi, it becomes the first oral liquid form of imatinib.
| Takeda is focused on curbing dengue with innovative solutions and public-private partnerships to achieve the WHO’s goal of zero dengue deaths by 2030.
For years, electronic data capture (EDC) systems have been the backbone of clinical trials, efficiently collecting and managing study data. The post Beyond Data Collection: How Modern EDC Systems Are Becoming Clinical Intelligence Hubs appeared first on Crucial Data Solutions.
Tune in to this podcast episode featuring an interview with Phil Johnson from Interius Biotherapeutics as he discusses the latest advancements in CAR-T therapies, focusing on faster, better, and cheaper treatments.
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Join the 15th World ADC London event organized by Hanson Wade in 2025. Explore the latest advancements in antibody-drug conjugates and network with industry experts.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, offers advice for effectively being able to adjust plans.
Presentation: Building Upon Quality by design and Risk-based Monitoring Implementation Momentum Date: Wednesday, June 18, 8:30 – 9:30 a.m. Presenter: Gerrit Hamre (Duke University), Morgan Hanger (CTTI), Sameera Ibrahim (Bristol Myers Squibb), and Alissa Munn (Food and Drug Administration/CDER) The post DIA Global Meeting 2025 appeared first on CTTI.
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content